Lack of efficacy of mefloquine in the treatment of new world cutaneous leishmaniasis in Colombia

ABSTRACT: In a nonblinded, therapeutic trial conducted in Colombia, 1.25–1.5 grams of mefloquine base given as a single oral dose or as 250 mg a day for 5–6 consecutive days was not efficacious in the treatment of New World cutaneous leishmaniasis. The drug had cured only 30.8% of patients with leis...

Full description

Autores:

Muñoz Herrera, Diana Lorena
Puerta Álvarez, Juan Alberto
Vélez Bernal, Iván Darío
Hendrickx, Erik Paul

Tipo de recurso:

Article of investigation

Fecha de publicación:

1998

Institución:

Universidad de Antioquia

Repositorio:

Repositorio UdeA

Idioma:

eng

OAI Identifier:

oai:bibliotecadigital.udea.edu.co:10495/32064

Acceso en línea:

https://hdl.handle.net/10495/32064

Palabra clave:

Antimaláricos
Antimalarials
Leishmaniasis Cutánea
Leishmaniasis, Cutaneous
Mefloquina
Mefloquine

Rights

openAccess

License

http://creativecommons.org/licenses/by-nc-nd/2.5/co/